ArticleCancer medicine2025
A Multicenter Study on Unnecessary Rebiopsies in CT-Guided Percutaneous Transthoracic Needle Biopsy of Pulmonary Lesions.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
BACKGROUND AND
objectiveComputed tomography-guided percutaneous transthoracic needle biopsy of pulmonary lesions (PTNBP) is widely used for diagnosing and managing lung cancer. However, rebiopsies are often required due to insufficient specimens for definitive pathological diagnosis and molecular testing, which increase patient burden and reduce treatment efficiency. This study aims to investigate the characteristics of rebiopsies and propose strategies to minimize unnecessary rebiopsies.
methodsA total of 12,882 PTNBP cases from three centers were analyzed from January 2018 to December 2022. Attribution analysis was conducted for the rebiopsy cases, and descriptive analysis was conducted for clinical parameters.
resultsThe rebiopsy rate was 6.5% (841/12,882), with 31.0% (261/841) of rebiopsies due to insufficient specimens. Among these cases, 87.0% (227/261) were stage III-IV, 89.7% (234/261) had poorly differentiated tumors, and 80.1% (209/261) were non-small cell lung cancer (NSCLC). The proportion of molecular testing in stage IV cases was significantly higher than in stage I-III cases (44.8% vs. 25.3%, p = 0.0022). Poorly differentiated cases required significantly more biomarkers in immunohistochemistry and special staining than moderately and well-differentiated cases (8.1 vs. 4.0, p = 0.0039). Insufficient tissue rates were significantly higher in cases with only one biopsy core compared to those with more cores (2.4% vs. 1.5%, p = 0.0088).
conclusionPatients with advanced-stage disease, poorly differentiated tumors, and NSCLC undergoing PTNBP are more likely to require rebiopsy due to insufficient specimens. Increasing the number of biopsy cores (≥ 2) and implementing one-stop management for pathological assessment may effectively reduce unnecessary rebiopsies in PTNBP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.